skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Executive Summary



Here's a graphical look at the global device approvals in 2016. It was another record year for novel devices in the US, while trends remained relatively steady in other regions.

 

 

Medical_devices_Medtech_Insight

 

 

Trends in medical device approvals say something about the direction of industry and the performance of regulators. Here's a graphical look at some key data points linked to device approvals in 2016, in the US, Europe and beyond.


For an analysis of the US approval trend see "US Approvals Analysis: 2016 Another Record Year For Novel Devices." For a closer look at the numbers out of the US, see "OUS Approvals Analysis: 2016 Finishes Slowly, But Still Beats 2015."


For sortable and searchable tables of all 2016 US and non-US approvals and clearances, check out our Approvals Tracker.

 

Infographic_device_Medtech_Insight

 

Read also

  • Biomedtracker: follow the drug development process

    Accurate, Intuitive and Updated In Real Time

    03 Apr 2017

    Learn why pharmaceutical, biotech, and investment companies rely on BioMedTracker for its insight on the likelihood of approval, commercial potential, and future data and regulatory catalysts for drugs within the competitive landscape of every important disease and indication.

  • Scrip: industry news and insights

    Bayer Bets On Oncology Pipeline Vows To Increase 2017 R&D Budget

    By Lucie Ellis 22 Feb 2017

    Bayer has launched an internal oncology R&D unit to speed up development of its pipeline cancer therapies and ensure the company is first to market with its late-stage treatment candidates, head of pharma Dieter Weinand told Scrip on the sidelines of the pharma's annual results conference.

    Topics Cancer Research

  • Biomedtracker: follow the drug development process

    Biomedtracker 2018 Early Outlook Report

    What’s on the horizon for pharma in 2018? Find out with Biomedtracker’s Early 2018 Outlook Report extract. Download free extracts from this essential report, which investigates the catalysts expected to occur in the first part of the year for 21 different drugs.

    Topics $name

;

Next steps

Whether you’re a small biotech start-up, research firm, generic manufacturer or a global pharmaceutical giant, you need focused, independent insight and opinion on market developments.

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: